These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 35010576)
1. Lymphatic Filariasis: A Systematic Review on Morbidity and Its Repercussions in Countries in the Americas. Medeiros ZM; Vieira AVB; Xavier AT; Bezerra GSN; Lopes MFC; Bonfim CV; Aguiar-Santos AM Int J Environ Res Public Health; 2021 Dec; 19(1):. PubMed ID: 35010576 [TBL] [Abstract][Full Text] [Related]
2. Information technology in morbidity management of human lymphatic filariasis-A promising tool in global programme for elimination of lymphatic filariasis. Devi RR; Raju V J Vector Borne Dis; 2018; 55(1):20-25. PubMed ID: 29916444 [TBL] [Abstract][Full Text] [Related]
3. Health economic analyses of the Global Programme to Eliminate Lymphatic Filariasis. Turner HC Int Health; 2020 Dec; 13(Suppl 1):S71-S74. PubMed ID: 33349885 [TBL] [Abstract][Full Text] [Related]
4. A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000-2020). Turner HC; Ottesen EA; Bradley MH Parasit Vectors; 2022 May; 15(1):181. PubMed ID: 35643508 [TBL] [Abstract][Full Text] [Related]
5. The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs. Mathew CG; Bettis AA; Chu BK; English M; Ottesen EA; Bradley MH; Turner HC Clin Infect Dis; 2020 Jun; 70(12):2561-2567. PubMed ID: 31343064 [TBL] [Abstract][Full Text] [Related]
6. The economic benefits resulting from the first 8 years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007). Chu BK; Hooper PJ; Bradley MH; McFarland DA; Ottesen EA PLoS Negl Trop Dis; 2010 Jun; 4(6):e708. PubMed ID: 20532228 [TBL] [Abstract][Full Text] [Related]
7. Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Addiss DG; Brady MA Filaria J; 2007 Feb; 6():2. PubMed ID: 17302976 [TBL] [Abstract][Full Text] [Related]
8. Factors Associated with the Acceptability of Mass Drug Administration for Filariasis: A Systematic Review. Abdul Halim AFN; Ahmad D; Miaw Yn JL; Masdor NA; Ramly N; Othman R; Kandayah T; Hassan MR; Dapari R Int J Environ Res Public Health; 2022 Oct; 19(19):. PubMed ID: 36232271 [TBL] [Abstract][Full Text] [Related]
9. Financial burden impact quality of life among lymphatic Filariasis patients. Asiedu SO; Kwarteng A; Amewu EKA; Kini P; Aglomasa BC; Forkuor JB BMC Public Health; 2021 Jan; 21(1):174. PubMed ID: 33478462 [TBL] [Abstract][Full Text] [Related]
10. [ Bancroftian lymphatic filariasis: toward its elimination from the Pacific?]. Chanteau S; Roux JF Bull Soc Pathol Exot; 2008 Jun; 101(3):254-60. PubMed ID: 18681220 [TBL] [Abstract][Full Text] [Related]
11. Developing the first national database and map of lymphatic filariasis clinical cases in Bangladesh: Another step closer to the elimination goals. Karim MJ; Haq R; Mableson HE; Sultan Mahmood ASM; Rahman M; Chowdhury SM; Rahman AKMF; Hafiz I; Betts H; Mackenzie C; Taylor MJ; Kelly-Hope LA PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007542. PubMed ID: 31306409 [TBL] [Abstract][Full Text] [Related]
13. Elimination of lymphatic filariasis: do we have the drugs to complete the job? Bockarie MJ; Deb RM Curr Opin Infect Dis; 2010 Dec; 23(6):617-20. PubMed ID: 20847694 [TBL] [Abstract][Full Text] [Related]
14. Evolution of the monitoring and evaluation strategies to support the World Health Organization's Global Programme to Eliminate Lymphatic Filariasis. Lammie PJ; Gass KM; King J; Deming MS; Addiss DG; Biswas G; Ottesen EA; Henderson R Int Health; 2020 Dec; 13(Suppl 1):S65-S70. PubMed ID: 33349883 [TBL] [Abstract][Full Text] [Related]
15. Elimination of lymphatic filariasis as a public health problem from the Arab Republic of Egypt. Ramzy RMR; Kamal HA; Hassan MA; Haggag AA Acta Trop; 2019 Nov; 199():105121. PubMed ID: 31400299 [TBL] [Abstract][Full Text] [Related]
16. Using intervention mapping to design and implement quality improvement strategies towards elimination of lymphatic filariasis in Northern Ghana. Manyeh AK; Ibisomi L; Baiden F; Chirwa T; Ramaswamy R PLoS Negl Trop Dis; 2019 Mar; 13(3):e0007267. PubMed ID: 30908495 [TBL] [Abstract][Full Text] [Related]
17. Is mass drug administration against lymphatic filariasis required in urban settings? The experience in Kano, Nigeria. Pam DD; de Souza DK; D'Souza S; Opoku M; Sanda S; Nazaradden I; Anagbogu IN; Okoronkwo C; Davies E; Elhassan E; Molyneux DH; Bockarie MJ; Koudou BG PLoS Negl Trop Dis; 2017 Oct; 11(10):e0006004. PubMed ID: 29020042 [TBL] [Abstract][Full Text] [Related]
18. Can malaria vector control accelerate the interruption of lymphatic filariasis transmission in Africa; capturing a window of opportunity? Kelly-Hope LA; Molyneux DH; Bockarie MJ Parasit Vectors; 2013 Feb; 6():39. PubMed ID: 23433078 [TBL] [Abstract][Full Text] [Related]
19. Physicians' management of filarial lymphoedema and hydrocele in Pondicherry, India. Schellekens SM; Ananthakrishnan S; Stolk WA; Habbema JD; Ravi R Trans R Soc Trop Med Hyg; 2005 Jan; 99(1):75-7. PubMed ID: 15550265 [TBL] [Abstract][Full Text] [Related]
20. Keeping communities at the centre of efforts to eliminate lymphatic filariasis: learning from the past to reach a future free of lymphatic filariasis. Krentel A; Gyapong M; McFarland DA; Ogundahunsi O; Titaley CR; Addiss DG Int Health; 2020 Dec; 13(Supplement_1):S55-S59. PubMed ID: 33349882 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]